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in lung cancer treatment is variable according to several items:
the country where the treatment is performed, hospitalization,
administration and drug costs. METHODS: A total of 344 Lung
cancer patients were selected within the records of a private
hospital in Brazil. Of those, 69 patients that received pemetrexed
or docetaxel as second line chemo. The chemotherapy protocols
considered were: Pemetrexed 500mg/m2 every 3 weeks, Doc-
etaxel 75mg/m2 every three weeks, Docetaxel 35mg/m2 weekly (3
times per cycle) and Docetaxel 40mg/m2 weekly (3 times per
cycle). HRU frequency (hospitalization, clinical visits, comple-
mentary examinations, medication, transfusions) related to lung
cancer treatment was reviewed retrospectively from clinical
records. The costs were calculated in dolars (US$) following the
original records for each cycle. The values for neutropenia were
also calculated. RESULTS: Pemetrexed 500mg/m2 every three
weeks was used by 20.5% of the patients; Docetaxel 75 mg/m2
every three weeks by 17.1%; Docetaxel 35mg/m2 weekly (3 times
per cycle) by 8.1% and Docetaxel 40mg/m2 weekly (3 times
per cycle) by 1.1%.The cost of each cycle was U$6897.00 for
Pemetrexed 500mg/m2; US$3041.00 for Docetaxel 75mg/m2;
US$5919.00 for Docetaxel 35mg/m2 and US$6669.00 for Doc-
etaxel 40mg/m2. The costs of neutropenia and febrile neutrope-
nia episodes were respectively US$1310.00 and US$6000.00.
CONCLUSION: Besides the cost of the drug is a mean point in
health resources utilization we have to consider other variables to
have a clear picture of each chemotherapy scheme costs and were
the resources have been used. Since the chance of toxicity is
different for every kind of treatment, all the inputs to reach the
total cost of treatment are necessary.
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OBJECTIVE: To determine the ﬁnancial impact of sorafenib in
the treatment of hepatocellular carcinoma (HCC), the most
common form of liver cancer, from a Canadian provincial drug
plan perspective for 2008–2010. METHODS: A prevalence-
based approach was used to estimate the number of HCC
patients in Canada. Liver cancer prevalence from 2008–2010
was estimated using the GLOBOCAN 2002 database, supple-
mented with actual and projected Canadian liver cancer inci-
dence ﬁgures from 2003–2010, and survival rates for each stage
of HCC. Liver cancer ﬁgures were condensed to HCC ﬁgures as
~90% of liver cancers are HCC. HCC ﬁgures were then seg-
mented using the Barcelona Clinic Liver Cancer staging system
and diagnosis rates provided the clinical community. Age and
geographic distribution patterns, market share assumptions and
provincial drug plan coverage factors were then applied to the
HCC ﬁgures to determine the number of HCC patients eligible
for treatment with sorafenib and coverage from the province.
Drug costs including wholesale and pharmacy mark ups were
multiplied with the median treatment duration and patient
number to determine the ﬁnancial impact of sorafenib.
RESULTS: The prevalence of liver cancer in Canada in 2008 has
been estimated to be 1284 increasing to 1324 by 2009 and 1366
by 2010. Of these an estimated 206 HCC patients will be treated
with sorafenib in 2008, increasing to 321 in 2009 and 438 in
2010. The number of HCC patients treated with sorafenib that
are eligible to receive coverage through their provincial drug plan
are 154, 240 and 328 in 2008, 2009 and 2010 respectively. The
ﬁnancial impact of sorafenib to the provincial drug plans is $3.7
million in 2008, $7.1 million in 2009 and $9.7 million in 2010.
CONCLUSION: The ﬁnancial impact of sorafenib to the pro-
vincial drug plans will range from $3.7 million to $9.7 million
from 2008–2010.
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OBJECTIVE: We sought to systematically review economic
analyses (EAs) of HER2 testing and trastuzumab therapy in all
stages of breast cancer (BC) with speciﬁc attention to the meth-
odological quality, quantiﬁcation of uncertainty and incorpora-
tion of diagnostic test characteristics. METHODS: EAs of
trastuzumab in BC or HER2 diagnosis with either immunohis-
tochemistry or ﬂuorescence in situ hybridisation techniques were
considered. Biosis, Cochrane, CRD, EconLit, Embase, HEED,
Medline and PubMed databases were searched. The reference
lists of each retrieved article, relevant reviews, and abstracts of
the San Antonio Breast Cancer Symposium were hand-searched.
Citations were reviewed in duplicate and relevant articles were
qualitatively rated per Drummond. RESULTS: Twenty studies,
conference abstracts and health technology assessments were
selected for full review from among 641 citations as of December
2007 (reviewer agreement kappa = 0.85). Studies examined tras-
tuzumab in metastatic (7/20) or adjuvant (10/20) settings or had
a testing focus (4/20). HER2 diagnosis strategy and trastuzumab
treatment were evaluated jointly in only one study. Few decision
models were calibrated against epidemiological data (3/20).
Probabilistic sensitivity analysis was infrequently used to charac-
terise uncertainty (3/20) and decision uncertainty in the form of
cost-effectiveness acceptability curves was presented in a single
study. The overall reported quality of EAs was comparatively
poor. CONCLUSION: Testing and treatment were rarely exam-
ined in tandem, despite a 2004 EA addressing this very issue in
metastatic disease. Given the controversy around trastuzumab
funding in many jurisdictions, the need for adequate attention to
testing and uncertainty analysis is not met in the literature.
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OBJECTIVE: Two vaccines against cervical cancer are now
available. One reduces the burden of genital warts; with the other
the model estimates it may have better cross-protection against
oncogenic non-vaccine HPV-types. We aimed to understand the
extent to which cross-protection could have an equivalent cost
impact and the likelihood this would occur. METHODS: A
population model was developed in Excel(r) to evaluate the
expected annual health care cost of protecting cervical diseases
with vaccines against speciﬁc HPV-types. The type-speciﬁc
vaccine effect was assessed on the number of abnormal pap
smears, pre-cancer lesions, genital warts and cervical cancer cases
prevented. Vaccine effect was calculated by multiplying the pro-
portion of HPV-types per lesion, as reported in the literature, by
a range of vaccine efﬁcacy values. A health care perspective was
selected, with unit costs (2006 CDN$) for each intervention
obtained from ofﬁcial tariff data. No discounting was applied as
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